Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

X
Search
Drug Profile

FX 005

Alternative Names: FX-005

Latest Information Update: 04 Mar 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer Flexion Therapeutics
  • Class Analgesics
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Musculoskeletal pain

Most Recent Events

  • 10 Mar 2017 Discontinued - Phase-I/II for Musculoskeletal pain in Spain, Austria, Canada and United Kingdom (Intra-articular)
  • 25 Sep 2015 FX 005 is still in phase-I/II development for Musculoskeletal pain in Austria, Canada, Spain and the United Kingdom
  • 30 May 2012 Interim efficacy and adverse events data from a phase I/II trial in Musculoskeletal pain released by Flexion Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days

Latest webinar now available!

Our latest webinar, Navigating the Complex Landscape of Clinical Trials: Trends, Global Impact, including Hits & Misses 2024, is available now. Key topics include an analysis of trials with both positive and negative outcomes, failed trials of 2024, and impactful trials of 2024 that contributed to regulatory approvals or company revenue, followed by an outlook on a few pivotal trials to watch in 2025.

Watch here!